Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KMT2D Deficiency Promotes Myeloid Leukemias which Is Vulnerable to Ribosome Biogenesis Inhibition

4 May 2023

Abstract excerpt

KMT2C and KMT2D are the most frequently mutated epigenetic genes in human cancers. While KMT2C is identified as a tumor suppressor in acute myeloid leukemia (AML), the role of KMT2D remains unclear in this disease, though its loss promotes B cell lymphoma and various solid cancers. Here, it is reported that KMT2D is downregulated or mutated in AML and its deficiency, through shRNA knockdown or CRISPR/Cas9...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Genomics and Chromatin Dynamics
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37142882
DOI: 10.1002/advs.202206098

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KMT2D Deficiency Promotes Myeloid Leukemias which Is Vulnerable to Ribosome Biogenesis InhibitionPMID 37142882Read ↗

Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapiesSemantic proximity Read ↗

Therapeutic Targeting of the Menin–KMT2A InteractionSemantic proximity Read ↗

Acute myeloid leukemias with <i>UBTF</i> tandem duplications are sensitive to menin inhibitorsSemantic proximity Read ↗

Epigenetic changes in human model KMT2A leukemias highlight early events during leukemogenesis.Semantic proximity Read ↗

Acute Myeloid Leukemias with Alterations of Lysine Methyltransferase 2A (KMT2A): Recent Therapeutic DevelopmentsSemantic proximity Read ↗

SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.Semantic proximity Read ↗

KMT2D preferentially binds mRNAs of the genes it regulates, suggesting a role in RNA processingSemantic proximity Read ↗

SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AMLSemantic proximity Read ↗

Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemiaSemantic proximity Read ↗

Histone H3 lysine 4 methyltransferase KMT2D.Semantic proximity Read ↗

The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependencySemantic proximity Read ↗

Molecular mechanisms of KMT2C alterations in gastrointestinal cancers: enhancer network destabilization, lineage plasticity, and clinical translation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.